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Background: It has been recently demonstrated that serum uric acid (UA) is associated with metabolic syndrome
(MetS) or its related clinical indications based on cross-sectional or prospective cohort studies. Nonetheless, due to
the fact that UA level constantly fluctuates from time to time even for the person, using a single measure of UA
level at baseline of those studies may not be sufficient for estimating the UA-Mets association.
Methods: To further estimate this time-dependent association, we fitted a generalized estimating equation (GEE)
regression model with data from a large-scale 6-year longitudinal study, which included 2222 participants
aged>=25 years with an average of 3.5 repeated measures of UA per person in the Health Management Center of
Shandong Provincial Hospital, Shandong, China.
Results: After adjusting for other potential confounding factors (i.e., total cholesterol, low-density lipoprotein), it
was verified that time-dependent UA level was an independent risk factor for MetS (OR = 1.6920, p< 0.0001). It was
found that UA level was positively associated with obesity, hypertension, and dyslipidemia, but was inversely
associated with hyperglycemia.
Conclusions: Serum UA level may serve as an important risk factor of MetS. Additionally, our study suggested that
UA level be an independent risk factor to obesity, hypertension and dyslipidemia, but a protective factor to
hyperglycemia. These findings are concordant with results from other studies on Asian populations, and jointly
provide a basis to further develop a risk assessment model for predicting MetS using UA levels and other factors in
China.Background
Metabolic syndrome (MetS) refers to a combination of med-
ical disorders ,including obesity, dyslipidemia, hypertension
and insulin resistance[1]. When occurring together, they in-
crease the risk of developing cardiovascular disease (CVD)
and diabetes [2]. Recent studies indicate a wider range of bio-
markers of MetS, e.g., alanine aminotransferase, white blood
cell count, gamma-glutamyltranspeptidase, and serum uric
acid (UA) [3, 4]. Based on cross-sectional studies, both posi-
tive and negative association between UA levels and MetS
has been reported [5-7]. To overcome the inherent limitation* Correspondence: xuefzh@sdu.edu.cn
†Equal contributors
1Department of Epidemiology and Health Statistics, School of Public Health,
Shandong University, PO Box 100, Jinan 250012, China
Full list of author information is available at the end of the article
© 2012 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orof cross-sectional design, a prospective cohort study was
conducted recently, which suggested that higher serum UA
level would strongly increase the risk of MetS incidence [8].
Nonetheless, such a cohort study with only baseline UA used
as predictor is still limited due to the fact that UA level
would vary from time to time during the lifespan of most
individuals [8]. Therefore, to fully understand the relationship
between UA and MetS, and further assess the specific associ-
ation between UA and each medical disorder in defining
MetS, longitudinal studies are expected especially those with
large sample sizes and repeated measures of UA. A longitu-
dinal study is usually a cohort study that involves repeated
observations of the same set of variables over a period of
time. Unlike cross-sectional studies or cohort studies with
only baseline measures, a longitudinal study not only tracks
each participant’s outcome (e.g., MetS) but also repeatedlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Therefore, longitudinal studies allow one to make observa-
tions more accurately and model time-dependent relation-
ships. They are more becoming popular in epidemiology and
biomedical research. In this paper, we study the UA-MetS
associations using data from a longitudinal study of male
residents who visited the Health Management Center of




In our longitudinal study, participants include 2222 male
residents of Shandong Province who visited HMCSPH (an
affiliate of organization of Shandong University) at least
three times for annual physical examinations between 2005
and 2010. During the 6 year follow-up, each participant on
average had 3.63±0.016 measures including serum UA
levels. For this study, we only included participants who
had not been diagnosed as having MetS at baseline. They
were all Chinese Han with baseline age between 25 and
91 years, all belong to middle and upper socioeconomic
classes. This study was approved by the Ethics Committee
of School of Public Health, Shandong University, and all
participants gave informed written consent.
Measurements
Blood samples were collected from participants after an
overnight fast of at least 12 hours. Height and weight were
measured on participants wearing light clothing without
shoes, and body mass index (BMI) was calculated as
weight (kg) divided by squared height (m). Blood pressure
was measured on right upper arm with participants in sit-
ting position after 5 minutes rest. Peripheral blood sam-
ples was obtained for measuring the following parameters:
glucose, total cholesterol (CHOL), low-density lipoprotein
(LDL), high-density lipoprotein (HDL), triglycerides, uric
acid (UA), gamma-glutamyltranspeptidase (GGT), serum
albumin (ALB), serum globulins (GLO), blood urea nitro-
gen (BUN), serum creatinine (CREA), hemoglobin (Hb),
hematokrit (HCT), mean corpuscular volume(MCV),
mean corpuscular hemoglobin (MCH), Red blood cell dis-
tribution width (RDW), white blood count (WBC), platelet
distribution width (PDW), mean platelet volume (MPV),
and thrombocytocrit (PCT). Data on smoking habits, alco-
hol intake, diet habits, sleeping quality, exercise frequency,
and other variables were obtained using standardized
questionnaire.
Definition of metS
Considering the physiological characteristics of our target
population, the diagnostic criteria recommended by Dia-
betes Branch of the Chinese Medical Association (CDS)
[9] was used in defining MetS in this study. An participantwas claimed as having MetS if he or she had three or more
of the following four medical conditions: (1) overweight or
obesity, i.e., BMI ≥25.0 Kg/M [2]; (2) hypertension, i.e.,
systolic blood pressure (SBC) ≥140 mmHg, or diastolic
blood pressure (DBP) ≥90 mmHg, or previously diagnosed
as hypertension; (3) dyslipidemia, i.e., fasting triglycerides
(TG) ≥1.7 mmol/L(110 mg/dl), or fasting high-density
(HDL) <0.9 mmol/L(35 mg/dl); (4) hyperglycemia was
defined as fasting blood-glucose (FPG) ≥6.1 mmol/L
(110 mg/dl), or 2 h Postmeal Glucose (PG) ≥7.8 mmol/L
(140 mg/dl),or previously diagnosed as hyperglycemia.
Missing data imputation
In our longitudinal study, there were some variables (see
Table 1) with missing values due to early withdrawal of the
participants or missing of certain physical examinations. To
handle missing values, the strategy of multiple imputation
(MI) was adopted where imputations were made using the
Markov Chain Monte Carlo (MCMC) algorithm imple-
mented in the MI Procedure of SAS 9.1.3 [10]. Then, each
imputed data set was analysed using GEE regression mod-
els. Finally the multiple set of estimators for parameters of
interest from the GEE analyses were combined to make
final inferences. Considering that the variables in our ana-
lysis were continuously distributed with arbitrary missing-
ness patterns, a multivariate normal distribution model was
assumed in the MI Procedure. As seen in Table 1, most of
the imputed variables had less than 10 % of missingness.
UA Levels and potential confounding factors
Before fitting a GEE model, the original continuous serum
UA measure was categorized into 4 levels using the 3 quar-
tiles (P25, P50 and P75) as cut-off values. As seen in Table 1,
potential confounding factors were also considered during
the GEE analysis.
Statistical analysis
Descriptive analyses were first conducted for the distribu-
tions of UA levels and potential covariates collected at the
baseline survey. Then, each variable of interest was com-
pared, using student’s t-test, between subjects with and
subjects without MetS at each follow-up interval (i.e., each
year baseline). To study the association between UA levels
and MetS, we first fitted simple GEE models, each with a
single predictor (i.e., the UA variable or any one of the
confounding factors). We finally fitted a multiple GEE re-
gression model. A covariate was added to the final mul-
tiple regression model only if it was found significant
(p< 0.05) in the single-predictor model. Note that the
GEE modelling strategy is capable of describing time-
dependent relationship between UA levels and the MetS
status (yes or no), after adjusting potential confounders.
All these variables are repeatedly measured during the 6-
year follow-up. Age at baseline was also added to the
Table 1 Definition of UA levels and potential
confounding factors and missingess rate
variables Assignments Missingess
Rate
UA qualified by their quartiles of P25, P50 and P75
every year; Q1: the UA level≤ P25, Q2:
P25< the UA level< P50, Q3: P50< the UA
level< P75, Q4: the UA level≥ P75
0
2005 2006 2007 2008 2009 2010
P25 297 323 302 306 307 323
P50 353 372 345 349 353 368
P75 406 419 392 397 401 416
GGT gamma-glutamyltranspeptidase , U/L 1 %
ALB serum albumin, g/L 1 %
GLO serum globulins, g/L 1 %
BUN blood urea nitrogen, mg/L 1 %
CREA serum creatinine, mg/dl 1 %
CHOL Total cholesterol, mg/dl 1 %
Hb Hemoglobin, g/L 1 %
HCT Hematokrit, % 1 %
MCV mean corpuscular volume, fL 1 %
MCH mean corpuscular hemoglobin, pg 1 %
RDW Red blood cell distribution width, % 1 %
WBC white blood count, 109g/L 1 %
PDW Platelet distribution width 1 %
MPV mean platelet volume, fL 1 %
PCT Thrombocytocrit, % 1 %
diet 0: Vegetarian, 1: meat-based, 2: normal, 3: sea
food
17 %
drinking 0: never, 1: seldom, 2: often, wine, 3: often beer,
4: often, Chinese spirits, 5: often, mixed all kinds
6 %





0: excellent, 1: well, 2: fair, 3: poor, 4: very poor 6 %
exercise 0: never, 1: seldom, 2: often or everyday 6 %
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fect. In each GEE model, ‘Logit’ was chosen as the link
function of GEE, because either MetS status is a binary
dependent variable. Following the same procedure, we
studied the association between UA levels and each one of
the four medical disorders in defining MetS (i.e., over-
weight/obesity, hypertension, dyslipidemia, and hypergly-
cemia), which were all defined as binary variables. All
statistical analysis was performed by SAS 9.1.3.
Results
Additional file 1: Table S1 in Supplement Materials
shows the distribution of UA levels and other potential
confounding factors at the baseline survey, and their dis-
tributions between subjects with and subjects withoutMetS at each follow-up interval (i.e., each year after
baseline). The table shows that the UA level and other
potential confounding factors in the MetS group were
generally higher than their counterparts in the non-
MetS group at each follow-up intervals (P< 0.05), al-
though some factors were not statistically significant at
some follow-up intervals. The numbers of participants at
each follow-up interval during the study period (Jan
2005 - Dec 2010) are also shown in the Supplemental
Materials; see Additional file 1: Table S2.
Table 2 shows the results of single-predictor GEE mod-
els for the UA levels and other potential confounding fac-
tors. It is seen that the UA level was strongly associated
with MetS (OR=1.2952; 95 % CI= 1.1864-1.4141; p
< .0001). Age, GGT, ALB, GLO, CHOL, Hb, MCV and
MCH and WBC were all significant predictors or con-
founders at the α=0.05 level. Other factors including
BUN, CREA, HCT, RDW, PDW, MPV, PCT, iet, drinking,
smoking, quality of sleep and exercise are not significant
at the α=0.05 level.
Table 3 illustrates the association between UA levels and
MetS status after adjusting other potential confounding
factors using the final multiple GEE model. It reveals that,
compared with the lowest level of UA (Q1), the highest
level of UA (Q4) was strongly associated with MetS status
with a positive relationship (OR=1.6920; 95 % CI=
1.3390-2.1381; p< 0.0001). Although not significant, the
ORs for Q2 and Q3 were all larger than 1.0, and an in-
creasing trend was seen in OR from Q2 to Q4.
The results on association of UA levels with each single
MetS component, are shown in Table 4, 5, 6 and 7 of the
Supplemental Materials, respectively for overweight/obes-
ity, hypertension dyslipidemia and hyperglycemia. Table 4
shows that UA was a strong independent risk factor to
overweight/obesity; and an obvious increasing trend in
OR is seen from Q2 to Q4 after adjusting the other three
components of MetS and potential confounding factors.
Table 6 and 4 jointly depict similar patterns for the associ-
ation between UA levels and hypertension or dyslipide-
mia, except that the OR is not significant at the Q2 level.
In contrast, UA is identified as a protective factor with the
range of ORs ranged from 0.58-0.74 after adjusting the
other three components and the same set of potential
confounding factors; see Table 7.
Discussions
The relationship among UA, MetS and cardiovascular dis-
eases has received much attention in recent years. The
findings from a nationwide representative sample of US
adults indicate that the prevalence of the MetS increases
substantially with increasing levels of UA [11]. UA as an
independent risk predictor for MetS also was found in Ko-
rean male workers aged 30–39 years [12], in Thai adults
receiving annual physical examinations [13], in Japanese











Quartiles of UA 0.2587 0.0448 5.78 <.0001 1.2952 1.1864 1.4141
age 0.0243 0.0031 7.94 <.0001 1.0246 1.0185 1.0308
GGT 0.0095 0.0012 8.15 <.0001 1.0095 1.0072 1.0118
ALB 0.037 0.0097 3.8 0.0001 1.0377 1.0181 1.0576
GLO −0.0574 0.0172 −3.33 0.0009 0.9442 0.9128 0.9766
BUN −0.0083 0.0431 −0.19 0.8474 0.9917 0.9114 1.0792
CREA −0.0004 0.0053 −0.08 0.933 0.9996 0.9894 1.0099
CHOL 0.3292 0.0491 6.7 <.0001 1.3899 1.2623 1.5304
Hb 0.0242 0.0052 4.67 <.0001 1.0245 1.0142 1.0350
HCT 0.0119 0.0173 0.69 0.4913 1.0120 0.9782 1.0470
MCV −0.0296 0.0112 −2.64 0.0083 0.9708 0.9496 0.9924
MCH 0.0905 0.0286 3.17 0.0015 1.0947 1.0351 1.1579
RDW −0.0613 0.0674 −0.91 0.3632 0.9405 0.8242 1.0734
WBC 0.1391 0.0276 5.05 <.0001 1.1492 1.0888 1.2130
PDW 0.0045 0.0299 0.15 0.8795 1.0045 0.9474 1.0651
MPV −0.0034 0.0623 −0.05 0.9563 0.9966 0.8821 1.1259
PCT −1.4813 1.0857 −1.36 0.1725 0.2273 0.0271 1.9092
diet −0.0248 0.0535 −0.46 0.6433 0.9755 0.8784 1.0834
drinking 0.0172 0.029 0.59 0.5539 1.0173 0.9611 1.0768
smoking 0.0044 0.0241 0.18 0.8536 1.0044 0.9582 1.0530
quality of sleep −0.0242 0.062 −0.39 0.696 0.9761 0.8644 1.1021
exercise 0.015 0.103 0.15 0.8841 1.0151 0.8295 1.2423
Table 3 The results of multiple GEE analysis for UA levels and MetS after adjusting other potential confounding factors




Intercept −5.3378 1.4182 −3.76 0.0002
Q4 0.5259 0.1194 4.41 <.0001 1.6920 1.3390 2.1381
Q3 0.1856 0.1244 1.49 0.1357 1.2039 0.9435 1.5363
Q2 0.0709 0.1274 0.56 0.5778 1.0735 0.8363 1.3780
Q1 0 0 ref ref ref ref ref
time 0.3072 0.026 11.84 <.0001 1.3596 1.2923 1.4306
baseage 0.0308 0.0034 9.16 <.0001 1.0313 1.0245 1.0381
GGT 0.0091 0.0011 7.96 <.0001 1.0091 1.0069 1.0115
ALB −0.018 0.018 −1 0.3197 0.9822 0.9481 1.0176
GLO 0.0228 0.0103 2.21 0.0268 1.0231 1.0026 1.0439
CHOL 0.1285 0.0468 2.74 0.0061 1.1371 1.0374 1.2463
Hb 0.012 0.0046 2.63 0.0086 1.0121 1.0031 1.0212
MCV −0.1321 0.019 −6.96 <.0001 0.8763 0.8443 0.9095
MCH 0.2862 0.0462 6.19 <.0001 1.3314 1.2160 1.4575
WBC 0.1531 0.0242 6.33 <.0001 1.1654 1.1115 1.2220
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Table 4 The results of multiple GEE analysis for UA levels and Obesity after adjusting other potential confounding
factors




Intercept −0.3359 0.8418 −0.4 0.6899
Q4 0.9224 0.0695 13.28 <.0001 2.5153 2.1953 2.8823
Q3 0.7133 0.0653 10.92 <.0001 2.0407 1.7955 2.3194
Q2 0.4271 0.0634 6.73 <.0001 1.5328 1.3536 1.7357
Q1 0 0 ref ref ref ref ref
hypertension 0.1446 0.0581 2.49 0.0128 1.1556 1.0312 1.2950
dyslipidemia 0.2913 0.0484 6.02 <.0001 1.3382 1.2170 1.4712
hyperglycemia −0.0503 0.0778 −0.65 0.5176 0.9509 0.8164 1.1075
time −0.0117 0.0191 −0.61 0.5417 0.9884 0.9520 1.0261
baseage 0.0055 0.0023 2.42 0.0155 1.0055 1.0010 1.0101
GGT 0.0061 0.0013 4.86 <.0001 1.0061 1.0036 1.0085
ALB −0.044 0.0096 −4.56 <.0001 0.9570 0.9390 0.9752
GLO −0.0075 0.0063 −1.2 0.2319 0.9925 0.9805 1.0048
CHOL 0.0115 0.0269 0.43 0.6702 1.0116 0.9595 1.0663
Hb 0.0188 0.0028 6.81 <.0001 1.0190 1.0135 1.0245
MCV −0.0147 0.0109 −1.34 0.179 0.9854 0.9646 1.0067
MCH −0.0155 0.0264 −0.59 0.5574 0.9846 0.9349 1.0370
WBC 0.0597 0.0162 3.68 0.0002 1.0615 1.0283 1.0959
Table 5 The results of multiple GEE analysis for UA levels and hypertension after adjusting other potential
confounding factors






Intercept −5.9514 1.0022 −5.94 <.0001
Q4 0.3953 0.0822 4.81 <.0001 1.4848 1.2639 1.7444
Q3 0.1751 0.0804 2.18 0.0294 1.1914 1.0178 1.3947
Q2 −0.0189 0.0808 −0.23 0.8146 0.9813 0.8375 1.1496
Q1 0 0 ref ref ref ref ref
hyperglycemia 0.345 0.0843 4.09 <.0001 1.4120 1.1969 1.6658
dyslipidemia −0.3991 0.0596 −6.69 <.0001 0.6709 0.5969 0.7541
obesity 0.1882 0.0584 3.22 0.0013 1.2071 1.0766 1.3534
time 0.101 0.0218 4.64 <.0001 1.1063 1.0600 1.1544
baseage 0.0686 0.0027 25.55 <.0001 1.0710 1.0655 1.0767
GGT 0.0077 0.001 7.62 <.0001 1.0077 1.0057 1.0097
ALB 0.0028 0.0119 0.23 0.8149 1.0028 0.9797 1.0263
GLO 0.0155 0.0071 2.19 0.0285 1.0156 1.0016 1.0298
CHOL 0.0216 0.0314 0.69 0.4923 1.0218 0.9608 1.0867
Hb 0.0135 0.0031 4.31 <.0001 1.0136 1.0074 1.0198
MCV −0.0276 0.0131 −2.1 0.0357 0.9728 0.9481 0.9982
MCH 0.0114 0.032 0.36 0.722 1.0115 0.9500 1.0768
WBC 0.0538 0.0186 2.8900 0.0039 1.0553 1.0175 1.0945
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and in many other populations. Particularly, the debate on
whether UA should be viewed even as an additional com-
ponent of MetS received intensive discussions [16]; and
the relationship between UA and each MetS component
was also controversial. In this paper, based on a large lon-
gitudinal cohort study over 6 years, we confirmed that UA
level is positively and significantly associated with risk of
MetS among healthy male adults in Han Chinese of Shan-
dong province, after adjusting other potential confounding
factors using GEE regression analyses. This provides us a
strong piece of evidence for developing risk assessment
model for early screening of MetS.
As an essential component of MetS, obesity was regarded
as a main contributor of the increasing prevalence of MetS,
because obesity was proved as a risk factor of hypertension,
dyslipidemia and hyperuricemia [17]. The positive gradient
of obesity with increasing UA level has been found among
several recent studies [18, 19]. In this study, we found con-
sistent results: in Chinese Han urban male population from
middle to upper socioeconomic classes, UA levels of Q2,
Q3, Q4 correspond to relative risks of 1.53, 2.04, and 2.51,
respectively, in getting obesity (with Q1 as reference level;
see Table 7. Additionally we found that the effect of UA on
obesity become much larger, compared to MetS; see Table 3.
In pathophysiology, it was explained in three ways for the
fact that obesity causes higher level of UA in blood: (1)Table 6 The results of multiple GEE analysis for UA levels and
confounding factors
Estimate Error Z
Intercept −0.4838 0.8527 −0.57
Q4 0.4752 0.0713 6.66
Q3 0.1815 0.067 2.71
Q2 0.0526 0.0659 0.8
Q1 0 0 ref
hyperglycemia 0.1725 0.0795 2.17
hypertension −0.4309 0.0603 −7.15
obesity 0.2916 0.0485 6.02
time −0.23 0.0196 −11.75
baseage −0.009 0.0023 −3.86
GGT 0.0106 0.0013 8.39
ALB 0.0005 0.01 0.05
GLO 0.0101 0.0063 1.59
CHOL −0.0465 0.027 −1.72
Hb 0.0108 0.0027 3.96
MCV −0.097 0.0114 −8.51
MCH 0.2093 0.0278 7.53
WBC 0.163 0.0166 9.8obesity directly interferes with urate synthesis and excretion
[20]; (2) obesity causes renal damage via glomerulus dys-
function [21]; (3) obesity leads to dysfunction of the renin-
angiotensin system, which would eventually results in frac-
tional clearance of UA [22].
The association between hyperglycemia and UA, how-
ever, still remained controversy. Most researches suggested
that hyperglycemia and UA should be the pathophysio-
logical underpinning of MetS a long time ago [23], and a
number of prospective studies have provided evidence that
individuals with higher UA are at a higher risk of diabetes
[9, 24, 25]. Nonetheless, some studies claimed that UA is
negatively associated with diabetes in Asian men [7, 12],
and an inverse association between UA and fasting plasma
glucose was also observed in adult residents of Taiwan [6].
In our study, also in Asian male population, Q2-Q4 of UA
was found to have lower risk of hyperglycemia with
adjusted OR from 0.58-0.74; see Table 5. This protective ef-
fect can be explained in two ways: (1) UA-hyperglycemia
association might be gender-dependent among Asian popu-
lations (i.e., UA is a risk factor in females, but a protective
factor in males); (2) the relationship might be nonlinear and
hyperglycemia could impair tubular reabsorption of UA [6,
26].
UA was first demonstrated to be associated with hyper-
tension by Mohamed in 1870 s [27], and in 2008, based on
the large population in the Normative Aging Study. Thedyslipidemia after adjusting other potential







<.0001 1.6083 1.3985 1.8498
0.0068 1.1990 1.0514 1.3672
0.4247 1.0540 0.9264 1.1993
ref ref ref ref
0.03 1.1883 1.0168 1.3886
<.0001 0.6499 0.5775 0.7315
<.0001 1.3386 1.2173 1.4720
<.0001 0.7945 0.7646 0.8256
0.0001 0.9910 0.9865 0.9956
<.0001 1.0107 1.0081 1.0131
0.9605 1.0005 0.9810 1.0204
0.1109 1.0102 0.9977 1.0229
0.085 0.9546 0.9054 1.0064
<.0001 1.0109 1.0055 1.0163
<.0001 0.9076 0.8875 0.9281
<.0001 1.2328 1.1674 1.3017
<.0001 1.1770 1.1393 1.2160
Table 7 The results of multiple GEE analysis for UA levels and hyperglycemia after adjusting other potential
confounding factors




Intercept −3.9156 1.2888 −3.04 0.0024
Q4 −0.3752 0.1069 −3.51 0.0004 0.6872 0.5573 0.8473
Q3 −0.5427 0.1084 −5.01 <.0001 0.5812 0.4700 0.7188
Q2 −0.3063 0.1026 −2.98 0.0028 0.7362 0.6021 0.9002
Q1 0 0 ref ref ref ref ref
hypertension 0.3269 0.0875 3.74 0.0002 1.3867 1.1681 1.6461
dyslipidemia 0.1672 0.0799 2.09 0.0363 1.1820 1.0108 1.3822
obesity 0.007 0.0774 0.09 0.9277 1.0070 0.8652 1.1721
time 0.2352 0.0279 8.43 <.0001 1.2652 1.1978 1.3363
baseage 0.0327 0.0033 10.03 <.0001 1.0332 1.0266 1.0399
GGT 0.0056 0.001 5.59 <.0001 1.0056 1.0036 1.0076
ALB 0.0218 0.016 1.36 0.1735 1.0220 0.9904 1.0545
GLO −0.0014 0.0093 −0.15 0.8834 0.9986 0.9805 1.0170
CHOL 0.2507 0.0405 6.19 <.0001 1.2849 1.1868 1.3911
Hb −0.0101 0.0041 −2.47 0.0136 0.9900 0.9820 0.9979
MCV −0.0935 0.0186 −5.04 <.0001 0.9107 0.8782 0.9445
MCH 0.2233 0.0436 5.12 <.0001 1.2502 1.1476 1.3618
WBC 0.0753 0.0236 3.1900 0.0014 1.0782 1.0294 1.1293
Zhang et al. BMC Public Health 2012, 12:419 Page 7 of 8
http://www.biomedcentral.com/1471-2458/12/419baseline UA was reported as a durable marker of risk of
hypertension [28]. In our longitudinal cohort study with
6 years of follow up, the GEE analyses confirmed that UA is
an independent risk factor of hypertension in Chinese Han
urban males; see Table 6. As found by Watanabe et al. [29],
once elevated UA level causes sufficient renal injury, human
body would develop salt-sensitive hypertension. Elevated
UA also associates with increased amount of free radicals
[30] and an oxidative stress, which may further abolish
endothelium-dependent vasodilatation [31].
Finally, it has been well received that elevated UA level
would increase the risk of dyslipidemia [12, 30]. Our longi-
tudinal study also suggests a positive association between
UA dyslipidemia; see Table 4. Although the role of UA in
the metabolism of triglycerides and other lipids still remains
unclear, it was believed that UA might be involved in either
the overproduction or the reduction of clearance of lipids
[32].
Conclusions
Association between UA and cardiovascular diseases has
been reported frequently recent years. Many research con-
firmed that UA was a strong risk factor for cardiovascular
diseases, especially MetS [33-35]. Our longitudinal study
further verified that UA is an independent risk factor of
MetS, higher level of UA leading to higher risk of MetS.
All the analyses were based on GEE regression models
with data from the longitudinal cohort study with HanChinese urban male participants who were from middle
to upper socioeconomic classes. Additionally, our study
suggested that UA level be an independent risk factor to
obesity, hypertension and dyslipidemia, but a protective
factor to hyperglycemia. These findings are concordant
with results from other studies on Asian populations, and
jointly provide a basis to further develop a risk assessment
model for predicting MetS using UA levels and other fac-
tors in China.
There were several limitations in the present study. Due
to the fact that participants of the study who came to the
hospitals mainly for physical examinations, they were man-
datorily asked to report histories on medication for treating
MetS or related medical disorders (e.g., hypertension). Thus
we did not have data on medication in our GEE regression
analyses in studying the UA–MetS association. Also consid-
ering that our study contains only local males from rela-
tively rich and educated families in Shandong province, and
the fact that our analyses only covered a follow-up period
of 6 years and no genetic information was included, it is
expected a large scale longitudinal study is expected for a
better and fully understanding of the target relationships.Additional file
Additional file 1: Table S1. The distribution of UA levels and other
potential confounding factors. Table S2 Numbers Participants at Each
Year of the Study
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